Drug Trial Radar · NCT02420379
Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy
Last checked: Nov 20, 2026Latest source record: Jan 25, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
33
Actual
Start
Jun 30, 2015
Primary completion
Dec 17, 2018
Study completion Dec 17, 2018
Sponsor
- Lead sponsor
- Sarepta Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 17, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 4 years, up to 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label study to assess the safety, tolerability, efficacy and pharmacokinetics of eteplirsen in patients with early stage Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.
Conditions
- Duchenne Muscular Dystrophy (DMD)
Interventions
eteplirsenDrug
Eteplirsen 30 mg/kg will be administered as an IV infusion once a week for 96 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to DiscontinuationTime frame: Baseline up to 100 weeks
- Number of Participants With Potentially Clinically Significant Laboratory Abnormalities Reported as TEAEsTime frame: Baseline up to 100 weeks
- Number of Participants With Potentially Clinically Significant Abnormalities in Vital Signs Reported as TEAEsTime frame: Baseline up to 100 weeks
- Number of Participants With at Least One Abnormal Physical Examination FindingTime frame: Baseline up to 100 weeks
- Number of Participants With Abnormalities in Electrocardiograms (ECGs) Reported as TEAEsTime frame: Baseline up to 96 weeks
- Number of Participants With Abnormalities in Echocardiograms (ECHO) Reported as TEAEsTime frame: Baseline up to 96 weeks
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Neuromuscular Research Center of Arizona
Phoenix, Arizona
Ronald Reagan UCLA Medical Center
Los Angeles, California
University of California, Davis Medical Center
Sacramento, California
Stanford University Medical Center
Stanford, California
University of Florida, Shands Hospital
Gainesville, Florida
Rare Disease Research Center
Atlanta, Georgia
Children's Hospital of Atlanta
Atlanta, Georgia
University of Iowa Children's Hospital
Iowa City, Iowa
St. Louis Children's Hospital
St Louis, Missouri
Nationwide Children's Hospital
Columbus, Ohio
Shriners Hospital for Children
Portland, Oregon
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Seattle Children's Hospital
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.